Modality
Gene Therapy
MOA
DLL3 ADC
Target
PCSK9
Pathway
Proteasome
OCDThymoma
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
~Dec 2020
→ ~Mar 2022
Phase 3
Jun 2022
→ Nov 2028
Phase 3Current
NCT07848630
807 pts·Thymoma
2023-04→2025-05·Recruiting
NCT08956838
1,113 pts·OCD
2025-10→2025-09·Terminated
NCT04210782
59 pts·Thymoma
2022-06→2027-10·Terminated
+1 more trial
2,715 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-05-1411mo agoPh3 Readout· Thymoma
2025-09-246mo agoPh3 Readout· OCD
2027-10-131.5y awayPh3 Readout· Thymoma
2028-11-152.6y awayPh3 Readout· OCD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Termina…
P3
Recruit…
P3
Recruit…
P3
Termina…
Catalysts
Ph3 Readout
2025-05-14 · 11mo ago
Thymoma
Ph3 Readout
2025-09-24 · 6mo ago
OCD
Ph3 Readout
2027-10-13 · 1.5y away
Thymoma
Ph3 Readout
2028-11-15 · 2.6y away
OCD
RecruitingTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07848630 | Phase 3 | Thymoma | Recruiting | 807 | EASI-75 |
| NCT08956838 | Phase 3 | OCD | Terminated | 1113 | BodyWt |
| NCT04210782 | Phase 3 | Thymoma | Terminated | 59 | BodyWt |
| NCT05781860 | Phase 3 | OCD | Recruiting | 736 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Talatapinarof | Samsung Biologics | Phase 1/2 | PCSK9 |